Antitumor activity of interleukin-18 on mouse glioma cells

被引：40

作者：

Kikuchi, T

Akasaki, Y

Joki, T

Abe, T

Kurimoto, M

Ohno, T

机构：

[1] Jikei Univ, Sch Med, Dept Oncol,Inst DNA Med, Minato Ku, Tokyo 1058461, Japan

[2] Jikei Univ, Sch Med, Dept Neurosurg, Tokyo 1058461, Japan

[3] Fujisaki Inst, Hayashibara Biochem Labs, Okayama, Japan

来源：

JOURNAL OF IMMUNOTHERAPY | 2000年 / 23卷 / 02期

关键词：

glioma; interleukin; 18; immunotherapy; tumor;

D O I：

10.1097/00002371-200003000-00002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Interleukin-18 (IL-18) exhibits antitumor activity in various laboratory models. In the current study, brain tumors in naive mice regressed after an intratumoral injection of a single dose of recombinant IL-18 (rIL-18). Intraperitoneal rIL-18 substantially delayed the growth of subcutaneously inoculated gliomas but not gliomas located in the brain. Efficacy was reduced when studies were performed in mice depleted of natural killer cells. Although intracerebral administration of rIL-18 increased the serum interferon-gamma concentration, the antitumor effect of IL-18 was not mediated by interferon-gamma. These data suggest the therapeutic potential for control of tumor growth by intratumoral administration of rIL-18 in patients with glioma.

引用

页码：184 / 189

页数：6

共 19 条

[1]

BRANDES A, 1991, ANTICANCER RES, V11, P1988

[2] Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis [J].

Coughlin, CM ;

Salhany, KE ;

Wysocka, M ;

Aruga, E ;

Kurzawa, H ;

Chang, AE ;

Hunter, CA ;

Fox, JC ;

Trinchieri, G ;

Lee, WMF .

JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (06) :1441-1452

[3] VACCINATION WITH IRRADIATED TUMOR-CELLS ENGINEERED TO SECRETE MURINE GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR STIMULATES POTENT, SPECIFIC, AND LONG-LASTING ANTITUMOR IMMUNITY [J].

DRANOFF, G ;

JAFFEE, E ;

LAZENBY, A ;

GOLUMBEK, P ;

LEVITSKY, H ;

BROSE, K ;

JACKSON, V ;

HAMADA, H ;

PARDOLL, D ;

MULLIGAN, RC .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (08) :3539-3543

[4] INTERLEUKIN-2 PRODUCTION BY TUMOR-CELLS BYPASSES T-HELPER FUNCTION IN THE GENERATION OF AN ANTITUMOR RESPONSE [J].

FEARON, ER ;

PARDOLL, DM ;

ITAYA, T ;

GOLUMBEK, P ;

LEVITSKY, HI ;

SIMONS, JW ;

KARASUYAMA, H ;

VOGELSTEIN, B ;

FROST, P .

CELL, 1990, 60 (03) :397-403

[5] INTERLEUKIN-7 INDUCES CD4+ T-CELL-DEPENDENT TUMOR REJECTION [J].

HOCK, H ;

DORSCH, M ;

DIAMANTSTEIN, T ;

BLANKENSTEIN, T .

JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (06) :1291-1298

[6]

Hyodo Y, 1999, J IMMUNOL, V162, P1662

[7]

Kikuchi T, 1999, INT J CANCER, V80, P425, DOI 10.1002/(SICI)1097-0215(19990129)80:3<425::AID-IJC15>3.0.CO

[8]

2-7

[9] In vivo antitumor effects of murine interferon-gamma-inducing factor/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites [J].

Micallef, MJ ;

Yoshida, K ;

Kawai, S ;

Hanaya, T ;

Kohno, K ;

Arai, S ;

Tanimoto, T ;

Torigoe, K ;

Fujii, M ;

Ikeda, M ;

Kurimoto, M .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 1997, 43 (06) :361-367

[10]

Micallef MJ, 1997, CANCER RES, V57, P4557

← 1 2 →